- Home
- UTG vs ACAD Comparison
UTG vs ACAD Comparison
Compare UTG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTG
- ACAD
- Stock Information
- Founded
- UTG 2003
- ACAD 1993
- Country
- UTG United States
- ACAD United States
- Employees
- UTG N/A
- ACAD N/A
- Industry
- UTG Investment Managers
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- UTG Finance
- ACAD Health Care
- Exchange
- UTG Nasdaq
- ACAD Nasdaq
- Market Cap
- UTG 2.8B
- ACAD 2.8B
- IPO Year
- UTG N/A
- ACAD 2004
- Fundamental
- Price
- UTG $32.79
- ACAD $16.32
- Analyst Decision
- UTG
- ACAD Buy
- Analyst Count
- UTG 0
- ACAD 17
- Target Price
- UTG N/A
- ACAD $24.00
- AVG Volume (30 Days)
- UTG 317.8K
- ACAD 1.5M
- Earning Date
- UTG 01-01-0001
- ACAD 05-07-2025
- Dividend Yield
- UTG 7.28%
- ACAD N/A
- EPS Growth
- UTG N/A
- ACAD N/A
- EPS
- UTG 9.86
- ACAD 1.36
- Revenue
- UTG $96,107,593.00
- ACAD $957,797,000.00
- Revenue This Year
- UTG N/A
- ACAD $13.07
- Revenue Next Year
- UTG N/A
- ACAD $9.97
- P/E Ratio
- UTG $3.20
- ACAD $12.00
- Revenue Growth
- UTG 8.35
- ACAD 31.85
- 52 Week Low
- UTG $25.26
- ACAD $14.15
- 52 Week High
- UTG $35.29
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- UTG 53.27
- ACAD 34.18
- Support Level
- UTG $32.31
- ACAD $16.86
- Resistance Level
- UTG $33.02
- ACAD $17.31
- Average True Range (ATR)
- UTG 0.44
- ACAD 0.51
- MACD
- UTG 0.07
- ACAD -0.03
- Stochastic Oscillator
- UTG 72.56
- ACAD 10.97
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.